Resonance Health Ltd · ASX:RHT
Resonance Health — Non-Deal Roadshow (December 2024)
17 slides from Resonance Health's roadshow presentation, Dec 2, 2024
Slide 1: Slide 1
Slide 2: Resonance Health Investor Presentation December 2024
Resonance Health Andrew Harrison, CEO Benjamin Carruthers, CFO Investor Presentation December 2024 1 1
Slide 3: The Resonance Business
The Resonance Business • Resonance Health is an ASX listed provider of Software-as-a Medical Device (SaMD), and Clinical Trial Services to Hospitals, Radiology Centres, and Pharma globally Revenue $10,000,000 • SaMD services are used in more than 400 locations globally $9,000,000 • Actively involved
Slide 4: Resonance Health specialises in central imaging analysis, CRO and investigator site services
Resonance Health specialises in providing central imaging analysis (SaMD) services, contract research organisation (CRO – Resonance Clinical) services and investigator site (TrialsWest) services to global pharmaceutical and biotechnology companies, hospitals and radiology centres. Central Imaging An
Slide 5: Recent historical performance
Recent historical performance The business has grown from $4.4M in reported group revenue in FY23 to $8.6M in reported group revenue in FY24 with an annualised run rate of $10.7M (assuming TrialsWest had been acquired on 1 July 2023). $4.4M Group Revenue $8.6M Group Revenue $10.7M Proforma Group Rev
Slide 6: Clinical Trial Ecosystem
Clinical Trial Ecosystem Clinical Trials are central to the development of new medicines and vaccines to prevent and treat disease. They require the coordinated action of numerous key stakeholders. Service Providers Pharma & Biotech Companies Certain activities may be outsourced by Sponsors/CROs to
Slide 7: FY24 Results Summary
FY24 Results Summary Revenue Normalised Operating EBITDA1 Normalised Operating $8.6M $1.12M EBITDA margin1 Up 95% pcp 13% Up 234% pcp Free Cashflow2 Free Cashflow / EPS $1.0M Operating EBITDA 0.04 CPS Up 314% pcp 90% Up 0.21 CPS pcp Net Cash $3.68M 1 Normalised Operating EBITDA = Statutory Net Profi
Slide 8: FY24 Highlights
FY24 Highlights ü Revenue of $8.6M, an increase of $4.2M or 95% on the prior corresponding period (PCP) Revenue ü Reported Normalised EBITDA of $0.69M, an increase of $1.5M or 183% on PCP $10,000,000 ü 1Normalised Operating EBITDA of $1.12M, an increase of $1.96M or 234% on the PCP at a $9,000,000 m
Slide 9: 1st Quarter FY25 Performance
1st Quarter FY25 Performance ü Receipts from customers for the first quarter of $3.2M - up 186% or $2.07M from pcp FY23 of $1.12M, ü Record cash receipts from customers over 12 months to 30 Sep 2024 of $10.2M up 133% or $5.8M from pcp to 30 Sep 2023 ü Uneven timing of revenue and costs relating the
Slide 10: Central Imaging Analysis (SaMD) Business
Central Imaging Analysis (SaMD) Business ü Analysis volumes and revenue increased in the SaMD business as compared to the prior year ü Entered into several new clinical trial service agreements to offer SaMD products into clinical trials as well as extending certain existing clinical trial service a
Slide 11: Resonance Clinical (CRO) Business
Resonance Clinical (CRO) Business ü Recent $13.78M contract illustrates success of CRO business strategy ü $20.1M in total contract wins since August 2023 ü Developed highly sophisticated CRO team capability ü Highly complementary business using both SaMD (FerriScan, HepaFat) and Trial Site (TrialsW
Slide 12: Investigator Sites
Investigator Sites ü Deal was struck to acquire TrialsWest in 3rd Quarter FY24 at that time, FY24 Revenue full year Revenue & EBITDA was forecast to be $2M & $0.667K Proforma TrialsWest FY Contribution respectively at a 33% operating margin ü Project wins and new trial commencements saw significant
Slide 13: Strong Path to Growth
Strong Path to Growth There are several key near term drivers of growth Early commercialisation of a non-invasive MRI Liver Fibrosis device Completion of Extended Proof of Concept study which will allow the early commercialization of the device as investigative use only into clinical trials whilst r
Slide 14: Strong Tailwinds
Strong Tailwinds Australian Clinical Trial Market Global Clinical Trial Market Key Drivers - Australia Key Drivers - Globally ü Approvals and regulatory system ü Increasing rapidity of technological breakthroughs ü Public private health system ü Shortening development timeframes ü Multi-cultural pop
Slide 15: Business Outlook
Business Outlook Strong FY25 Performance is expected on the back of strong FY24 results ü Continued growth in SaMD business volumes ü Current CRO clinical trial will continue to generate revenue in FY25 (expected to be completed during the year) ü New CRO contract win of $13.78M over ~24-month term
Slide 16: Disclaimer
Disclaimer This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual results to differ mater
Slide 17: Contact Us
Contact Us info@resonancehealth.com +61 8 9286 5300 resonancehealth.com resonance-health-ltd/